Advertisement

Topics

IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout

15:55 EDT 3 Aug 2017 | Xconomy

Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

Original Article: IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout

NEXT ARTICLE

More From BioPortfolio on "IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...